<4d6963726f736f667420576f7264202d208ca48b868bc690d18f578ef38fdc97f02e646f63>

Ueda S, Yamagishi S, Okuda S. New pathways to renal damage: Role of ADMA for retarding renal disease progression. J Nephrol, 23; 377-386, 2010
Matsui T, Yamagishi SI, Takeuchi M, Ueda S, Fukami K, Okuda S. Nifedipine inhibits advanced glycation end products (AGEs) and their receptor (RAGE) interaction-mediated proximal tubular cell injury via peroxisome proliferator-activated receptor-gamma activation. Biochem Biophys Res Commun. 398: 326-30, 2010
Fukami K, Yamagishi SI, Okuda S. Development of enzyme-linked immunosorbent assay system for PEDF and its clinical utility. Curr Mol Med. 10: 317-20, 2010
Ueda S, Yamagishi SI, Okuda S. Anti-vasopermeability effects of PEDF in retinal-renal disorders. Curr Mol Med. 10: 279-283, 2010
Yoshimura J, Fukami K, Koike K, Nagano M, Matsumoto T, Iwatani R, Kusumoto T, Hazama T, Ueda S, Adachi H, Hirai Y, Takasu K, Ohshima K, Yamagishi SI, Okuda S. Interstitial Foxp3-positive T cells may predict renal survival in patients with myeroperoxidase anti-neutrophil cytoplasmic antibody (MPO-ANCA)-associated glomerulonephritis. Clin Exp Pharmacol Physiol. 37: 879-83, 2010
Matsui T, Yamagishi S, Takeuchi M, Ueda S, Fukami K, Okuda S. Irbesartan inhibits albumin-elicited proximal tubular cell apoptosis. Protein Pept Lett, 17:74-77, 2010
Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Ueda Y, Suzuki T, Ueda S, Fukami K, Okuda S, Yamagishi SI. Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner. Pharmacol Res. 61: 58-61, 2010.
Matsui T, Yamagishi SI, Takeuchi M, Ueda S, Fukami K, Okuda S. Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression. Pharmacol Res. 61: 34-39,
Ueda S, Yamagishi S, Matsumoto Y, Kaida Y, Fujimi-Hayashida A, Koike K, Tanaka H, Fukami K, Okuda S. Involvement of asymmetric dimethylarginine (ADMA) in glomerular capillary loss and sclerosis in a rat model of chronic kidney disease (CKD) Life Sciences, 84: 853-856, 2009
Matsui T, Yamagishi S, Takeuchi M, Ueda S, Fukami K, Okuda S. Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation. Biochem Biophys Res
Commun., 385: 269-72, 2009
Coughlan MT, Thorburn DR, Penfold SA, Laskowski A, Harcourt BE, Sourris KC, Tan AL, Fukami K, Thallas-Bonke V, Nawroth PP, Brownlee M, Bierhaus A, Cooper ME, Forbes JM. RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol. 20: 742-52, 2009
Nakamura T, Sata E, Fujiwara N, Kawagoe Y, Suzuki T, Ueda Y, Ueda S, Adachi H, Okuda S, Yamagishi S. Ezetimibe decrease serum levels of asymmetric dimethylarginine (ADMA) and ameliorates renal injury in non-diabetic chronic kidney disease patients in a cholesterol-independent manner. Pharmacol Res., 60: 525-528, 2009
Nakamura T, Sata E, Fujiwara N, Kawagoe Y, Suzuki T, Ueda Y, Yamada S, Shoji H, Takeuchi M, Matsui T, Ueda S, Adachi H, Okuda S, Yamagishi S. Circulating levels of advanced glycation end products (AGE) and interleukin-6 (IL-6) are independent determinants of serum asymmetric dimethylarginine (ADMA) levels in patients with septic shock. Pharmacol. Res.,
Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Ueda Y, Suzuki T, Yamada S, Takeuchi M, Fukami K, Ueda S, Adachi H, Matsui T, Okuda S, Yamagishi S. Positive association of serum levels of advanced glycation end products (AGEs) and high mobility group box-1 (HMGB-1) with asymmetric dimethylarginine (ADMA) in non-diabetic chronic kidney disease patients. Metabolism, 58: 1624-1628, 2009
Shibata R, Ueda S, Yamagishi S, Kaida Y, Matsumoto Y, Fukami K, Hayashida A, Matsuoka H, Kato S, Kimoto M, Okuda S. Involvement of asymmetric dimethylarginine (ADMA) in tubulointerstitial ischemia in early phase of diabetic nephropathy. Nephrol Dial
Transplant. 24: 1162-1169, 2009
Fujimura T, Yamagishi S, Ueda S, Fukami K, Shibata R, Matsumoto Y, Kaida Y, Hyayashida A, Koike K, Matsui T, Nakamura K, Okuda S. Administration of pigment epithelium-derived factor (PEDF) reduces proteinuria by suppressing decreased nephrin and increased VEGF expression in the glomeruli of adriamycin-injected rats. Nephrol Dial Transplant.
Yamagishi S, Matsui T, Ueda S, Fukami K, Okuda S. Clinical utility of acarbose, alpha-glucosidase inhibitor on cardiometabolic disorders. Curr Drug Metab.;10:
Nagano M, Fukami K, Yamagishi SI, Ueda S, Kaida Y, Matsumoto T, Yoshimura J, Hazama T, Takamiya Y, Kusumoto T, Gohara S, Tanaka H, Adachi H, Okuda S. Circulating Matrix Metalloproteinase-2 is an independent correlate of proteinuria in patients with chronic kidney disease. Am J Nephrol. 29:109-115, 2008
Gore Y, Starlets D, Maharshak N, Becker-Herman S, Kaneyuki U, Leng L, Bucala R, Shachar I. Macrophage migration inhibitory factor induces B cell survival by activation of a CD74-CD44 receptor complex. J Biol Chem. 283: 2784-92, 2008
Gohara S, Shichijo S, Komatsu N, Okuda S, Yutani S, Itoh K. Detection of IgE antibody specific to a hepatitis C virus-derived peptide being recognized by cellular immunity in patients with HCV infection. Viral Immunol. 21:365-9, 2008
Yamagishi S, Ueda S, Nakamura K, Matsui T, and Okuda S. Role of Asymmetric Dimethylarginine (ADMA) in Diabetic Vascular Complications. Curr Pharm Des 14:
Thallas-Bonke V, Thorpe SR, Coughlan MT, Fukami K, Yap FY, Sourris KC, Penfold SA, Bach LA, Cooper ME, Forbes JM. Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabetes. 57: 460-9, 2008
Yamagishi S, Nakamura K, Matsui T, Ueda S, Fukami K, Okuda S. Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. Expert Opin Investig Drugs.
Ueda S, Yamagishi S, Fukami K, Hayashida A, Kaida Y, Takamiya Y, Okuda S. Implication of asymmetric dimethylarginine (ADMA) in endothelial cell growth process in atherosclerosis. Cell Growth Processes: New Research. Chapter IV, 123-137, 2008. (Nova publishers)
Fukami K, Yamagishi S, Ueda S, Okuda S. Role of AGEs in diabetic nephropathy. Current
Pharm Design, 14: 946-952, 2008
Yamagishi S, Ueda S, Matsui T, Nakamura K, Okuda S. Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy. Curr Pharm Des. 14:962-8,
Yamagishi S, Matsui T, Nakamura K, Inoue H, Takeuchi M, Ueda S, Fukami K, Okuda S, Imaizumi T. Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression. Microvasc Res
Yoshida Y, Yamagishi S, Ueda S, Okuda S, Yamakawa R. Aqueous humor levels of asymmetric dimethylarginine (ADMA) are positively associated with monocyte chemoattractant protein-1 (MCP-1) in patients with uveitis. Br J Ophthalmol. 92(1):93-4,
Ueda S, Yamagishi S, Kaida Y, Okuda S. Asymmetric dimethylarginine (ADMA) may be a missing link between cardiovascular disease (CVD) and chronic kidney disease (CKD). Nephrology 12: 582-590, 2007
Matsumoto Y, Ueda S, Yamagishi S, Matsuguma K, Shibata R, Fukami K, Matsuoka H, Imaizumi T, Okuda S. Dimethylarginine dimethylaminohydrolase prevents progression of renal dysfunction by inhibiting loss of peritubular capillaries and tubulointerstitial fibrosis in a rat model of chronic kidney disease. J Am Soc Nephrol. 18:1525-1533, 2007
Lassila M, Fukami K, Jandeleit-Dahm K, Semple T, Carmeliet P, Cooper ME, Kitching AR. Plasminogen activator inhibitor-1 production is pathogenetic in experimental murine diabetic renal disease. Diabetologia. 50: 1315-26, 2007
Forbes JM, Fukami K, Cooper ME. Diabetic nephropathy: where hemodynamics meets metabolism. Exp Clin Endocrinol Diabetes. 115: 69-84, 2007
Ueda S, Yamagishi S, Takamiya Y, Kaida Y, Okuda S. Asymmetric dimethylarginine (ADMA) and endothelial dysfunction in patients with chronic kidney disease. Research Advances in
Nephrology. 1: 1-12, 2007
Yoshimura J, Kato S, Tamaki K, Kohno K, Kaneyuki U, Maeda M, Saikusa-Itoh Y, Hayashida A, Iida S, Suefuji H, Okuda S. Mesangiolytic glomerulopathy after radiotherapy and chemotherapy of gastric lymphoma. Intern Med. 46: 1861-5, 2007
Yoshida Y, Yamagishi S, Ueda S, Yoshimura K, Okuda S, Yamakawa R. Aqueous humor levels of asymmetric dimethylarginine (ADMA) are correlated with pigment epithelium-derived factor (PEDF) in patients with uveitis. J Int Med Res 35: 892-895, 2007
Ueda S, Yamagishi S, Matsumoto Y, Okuda S. Role of asymmetric dimethylarginine (ADMA) in chronic kidney disease. Current Enzyme Inhibition 3: 284-290, 2007
Yamagishi S, Ueda S, Matsui T, Nakamura K, Imaizumi T, Takeuchi M, Okuda S. Pigment epithelium-derived factor prevents advanced glycation end products-elicited endothelial nitric oxide synthase reduction through its ant-oxidative properties. Protein Pept Lett 14: 832-5,
Yamagishi S, Matsui T, Nakamura K, Inoue H, Takeuchi M, Ueda S, Okuda S, Imaizumi T. Olmesartan blocks advanced glycation end product (AGE)-evoked inflammatory reactions in endothelial cells by suppressing reactive oxygen species generation. Ophthalmic Res, 40:
Yamagishi S, Ueda S, Okuda S. Food-derived advanced glycation end products (AGEs): A novel therapeutic target for various disorders. Current Pharmaceutical Design 13: 2832-6.
Matsui T, Yamagishi S, Ueda S, Nakamura K, Imaizumi T, Takeuchi M, Inoue T. Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end product (AGE)-induced monocyte chemoattractant protein-1 (MCP-1) expression in mesangial cells through down-regulation of receptor for AGEs (RAGE) via peroxisome proliferator-activated receptor-γ activation. J Int Med Res 35: 482-9, 2007.
Ueda S, Yamagishi S, Matsumoto Y, Fukami K, Okuda S. Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and development of renal injury in chronic kidney disease. Clin Exp Nephrol 11:115-121, 2007
Yamagishi S, Ueda S, Okuda S. A possible involvement of crosstalk between advanced glycation end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor in accelerated atherosclerosis in diabetes Med Hypotheses 69:
Yamagishi S, Fukami K, Ueda S, Okuda S. Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Current Drug Targets. 8: 952-9, 2007
Fukami K, Yamagishi S, Ueda S, Okuda S. Novel therapeutic targets for diabetic nephropathy. Endocr Metab Immune Disord Drug Targets 7: 83-92, 2007
Kaneyuki U, Ueda S, Yamagishi SI, Kato S, Fujimura T, Shibata R, Hayashida A, Yoshimura J, Kojiro M, Oshima K, Okuda S. Pitavastatin inhibits lysophosphatidic acid-induced proliferation and monocyte chemoattractant protein-1 expression in aortic smooth muscle cells by suppressing Rac-1-mediated reactive oxygen species generation. Vascul Pharmacol. 46:
Koike K, Iida S, Usui M, Matsumoto Y, Fukami K, Ueda S, Tamaki K, Kato S, Okuda S. Adult-onset acute tubulointerstitial nephritis and uveitis with fanconi syndrome. Case report and review of the literature. Clin Nephrol. 67:255-9, 2007
Tanaka M, Komatsu N, Terakawa N, Yanagimoto Y, Oka M, Sasada T, Mine T, Gouhara S, Shichijo S, Okuda S, Itoh K. Increased levels of IgG antibodies against peptides of the prostate stem cell antigen in the plasma of pancreatic cancer patients. Oncol Rep. 18: 161-6, 2007
Matsuguma K, Ueda S, Yamagishi S, Matsumoto Y, Kaneyuki U, Shibata R, Fujimura T, Matsuoka H, Kimoto M, Kato S, Imaizumi T, Okuda S. Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease. J Am
Soc Nephrol. 17:2176-83, 2006
Ueda S, Yamagishi S, Takeuchi M, Kohno K, Shibata R, Matsumoto Y, Kaneyuki U, Fujimura T, Hayashida A, Okuda S. Oral adsorbent AST-120 decreases serum levels of AGEs in patients with chronic renal failure. Mol Med, 12:180-184, 2006
Ueda S, Yamagishi S, Kaneyuki U, Okuda S. Asymmetric dimethylarginine (ADMA) and cardiovascular disease. Vasc Dis Prevent, 3:291-295, 2006
Iida S, Kohno K, Yoshimura J, Ueda S, Usui M, Miyazaki H, Nishida H, Tamaki K, Okuda S. Carbonic-adsorbent AST-120 reduces overload of indoxyl sulfate and the plasma level of TGF-β1 in patients with chronic renal failure. Clin Exp Nephrol 10:262-7, 2006.
Tanaka M, Komatsu N, Yanagimoto Y, Oka M, Shichijo S, Okuda S, Itoh K. Development of a new diagnostic tool for pancreatic cancer: simultaneous measurement of antibodies against peptides recognized by cytotoxic T lymphocytes. Kurume Med J. 53: 63-70, 2006
Kumashiro R, Koga Y, Kuwahara R, Ide T, Hino T, Tanaka K, Hisamochi A, Ogata K, Takao Y, Koga H, Nishida H, Okuda S, Sakamoto T, Sata M. Granulocytapheresis (GCAP) for severe alcoholic hepatitis-A preliminary report. Hepatol Res. 36:229-36, 2006
Fukami K, Cooper ME, Forbes JM. Expert Opin Investig Drugs. 14: 279-94, 2005
Kume S, Kato S, Yamagishi S, Inagaki Y, Ueda S, Arima N, Okawa T, Kojiro M, Nagata K. Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone. J Bone Miner Res
Yamagishi S, Nakamura K, Ueda S, Kato S, Imaizumi T. Pigment epithelium-derived factor (PEDF) blocks angiotensin II signaling in endothelial cells via suppression of NADPH oxidase: a novel anti-oxidative mechanism of PEDF. Cell Tissue Res. 320:437-45, 2005
Matsuura T, Yamagishi S, Kodama Y, Shibata R, Ueda S, Narama I. Otsuka Long-Evans Tokushima fatty (OLETF) rat is not a suitable animal model for the study of angiopathic diabetic retinopathy. Int J Tissue React. 27:59-62, 2005
Kaida H, Ishibashi M, Nishida H, Baba K, Hiromatsu Y, Okuda S, Hayabuchi N. Assessment of therapeutic effect in patients with secondary hyperparathyroidism using bone scintigraphy. Ann Nucl Med. 19: 367-72, 2005
Nishida H, Kaida H, Ishibashi M, Baba K, Kouno K, Okuda S. Evaluation of exercise-induced acute renal failure in renal hypouricemia using Tc-99m DTPA renography. Ann Nucl Med. 19:
Kaida H, Ishibashi M, Nishida H, Baba K, Hiromatsu Y, Okuda S, Hayabuchi N. Usefulness of whole PTH assay in patients with renal osteodystrophy--correlation with bone scintigraphy. Ann Nucl Med. 19: 179-84, 2005
Nishida H, Kaida H, Ishibashi M, Hiromatsu Y, Baba K, Iida S, Okuda S. Usefulness of bone uptake ratio of bone scintigraphy in hemodialysis patients. Ann Nucl Med. 19: 91-4, 2005
Nishida H, Ishibashi M, Hiromatsu Y, Kaida H, Baba K, Miyake I, Ikedo H, Kato S, Fukami K, Iida S, Okuda S. Comparison of histological findings and parathyroid scintigraphy in hemodialysis patients with secondary hyperparathyroid glands. Endocr J. 52: 223-8, 2005
Fukami K, Ueda S, Yamagishi S, Kato S, Inagaki Y, Takeuchi M, Motomiya Y, Bucala R, Iida S, Tamaki K, Imaizumi T, Cooper ME, Okuda S. AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction. Kidney Int. 66:2137-47, 2004
Ueda S, Kato S, Matsuoka H, Kimoto M, Okuda S, Morimatsu M, Imaizumi T. Regulation of cytokine-induced nitric oxide synthesis by asymmetric dimethylarginine: role of dimethylarginine dimethylaminohydrolase. Circ Res. 92:226-33, 2003
Ikedo H, Tamaki K, Ueda S, Kato S, Fujii M, Ten Dijke P, Okuda S. Smad protein and TGF-beta signaling in vascular smooth muscle cells. Int J Mol Med. 11(5):645-50, 2003.
Kato S, Ueda S, Yamaguchi M, Miyamoto T, Fujii T, Izumaru S, Kume S, Toyozum i Y,Arima N, Morimatsu M. Oever expression of p21Waf1 induces apoptosis in immo rtalized human vascular smooth muscle cells. J Atheroscler Thromb. 10:239-245,2003
Tamaki K, Okuda S. Role of TGF-beta in the progression of renal fibrosis. Contrib
Nephrol. 139:44-65, 2003
Haramaki R, Tamaki K, Fujisawa M, Ikedo H, Haramaki N, Okuda S. Steroid therapy and urinary transforming growth factor-beta1 in IgA nephropathy. Am J Kidney Dis. 38: 1191-8,
Kato S, Ueda S, Tamaki K, Fujii M, Miyazono K, Peter ten Dijke, Morimatsu M, Okuda S. Ectopic expression of Smad 7 inhibits transforming growth factor-b responses in vascular smooth muscle cells. Life sciences 69:2641-2652, 2001
Kohno K, Matsuoka H, Takenaka K, Miyake Y, Okuda S, Nomura G, Imaizumi T. Depressor effect by exercise training is associated with amelioration of hyperinsulinemia and sympathetic overactivity. Intern Med. 39: 1013-9, 2000
Miyazaki H, Matsuoka H, Usui M, Ueda S, Okuda S, Imaizumi T. Hemodialysis impairs endothelial function via oxidative stress - effect of vitamin E-coat dialyzer- Circulation 101:
Fujisawa M, Haramaki R, Miyazaki H, Imaizumi T, Okuda S. Role of lipoprotein (a) and TGF-beta 1 in atherosclerosis of hemodialysis patients. J Am Soc Nephrol. 11: 1889-95, 2000
Ueda S, Matsuoka H, Miyazaki H, Usui M, Okuda S, Imaizumi T. Tetrahydrobiopterin restores endothelial function in chronic smokers. J Am Coll Cardiol. 35: 71-75, 2000
Kohno K, Katayama T, Majima K, Fujisawa M, Iida S, Fukami K, Ueda S, Nishida H, Sata M, Kato S, Morimatu M, Okuda S. A case of normotensive scleroderma renal crisis after high-dose methylprednisolone treatment. Clin Nephrol. 53:479-82, 2000.
Boger RH, Bode-Boger SM, Matsuoka H, Miyazaki H, Usui M, Ueda S, Okuda S, Imaizumi T, Cooke JP. Is asymmetric dimethylarginine a novel marker of atherosclerosis? Circulation.
Kohno K, Mizuta Y, Yoshida T, Watanabe H, Nishida H, Fukami K, Iida S, Haramaki R, Wada Y, Tamai O, Tamaki K, Kato S, Morimatsu M, Okuda S. Nephrol Dial Transplant. 15: 1056-9,
Hiromatsu Y, Ishibashi M, Nishida H, Okuda S, Miyake I. Technetium-99m tetrofosmin parathyroid imaging in patients with primary hyperparathyroidism. Intern Med. 39: 101-6,
2009 年 第一回 腎疾患と高血圧研究会 奨励賞 2009 年 CKD award 2009 ポスター奨励賞 2008 年 KD award 2009 ポスター奨励賞 2008 年 医療・介護・教育研究財団 第４回ふくおか「臨床医学研究賞」 2007 年 第 7 回日本 NO 学会 Young investigator award (最優秀賞) 2007 年 第 44 回欧州透析移植学会 Best abstract award 2003 年 循環器学研究振興財団 奨励賞

Source: http://jin-jin.lolipop.jp/img/kouza/jisseki.pdf